Summary
6.59 -0.11(-1.64%)10/04/2024
Solid Biosciences Inc (SLDB)
Solid Biosciences Inc (SLDB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.64 | -6.52 | -22.56 | 12.27 | -46.51 | 180.43 | -95.62 | -98.06 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 6.59 | |
| Open | 6.82 | |
| High | 6.95 | |
| Low | 6.53 | |
| Volume | 160,628 | |
| Change | -0.11 | |
| Change % | -1.64 | |
| Avg Volume (20 Days) | 177,507 | |
| Volume/Avg Volume (20 Days) Ratio | 0.90 | |
| 52 Week Range | 1.81 - 15.05 | |
| Price vs 52 Week High | -56.21% | |
| Price vs 52 Week Low | 264.09% | |
| Range | -3.37 | |
| Gap Up/Down | 0.09 | |
Fundamentals | ||
| Market Capitalization (Mln) | 281 | |
| EBIDTA | -96,527,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 9.58 | |
| Book Value | 2.0250 | |
| Earnings Per Share | -0.7940 | |
| EPS Estimate Current Quarter | -0.2000 | |
| EPS Estimate Next Quarter | -0.2200 | |
| EPS Estimate Current Year | -0.7200 | |
| EPS Estimate Next Year | -0.8300 | |
| Diluted EPS (TTM) | -0.7940 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -7.1612 | |
| Return on asset (TTM) | -0.3236 | |
| Return on equity (TTM) | -0.6103 | |
| Revenue TTM | 10,466,000 | |
| Revenue per share TTM | 0.1110 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.8691 | |
| Revenue Enterprise Value | 0.3951 | |
| EBITDA Enterprise Value | 0.4637 | |
| Shares | ||
| Shares Outstanding | 110,296,000 | |
| Shares Float | 42,560,866 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.74 | |
| Institutions (%) | 70.66 | |
10/02 16:15 EST - globenewswire.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 51,338 restricted stock units (“RSUs”) to three newly hired employees.
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 51,338 restricted stock units (“RSUs”) to three newly hired employees.
09/12 08:00 EST - globenewswire.com
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 am ET.
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 am ET.
08/13 16:08 EST - globenewswire.com
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 –
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 –
07/01 16:19 EST - globenewswire.com
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
05/20 06:00 EST - investorplace.com
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.
05/15 12:53 EST - investorplace.com
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024
Solid Biosciences (NASDAQ: SLDB ) just reported results for the first quarter of 2024. Solid Biosciences reported earnings per share of -64 cents.
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024
Solid Biosciences (NASDAQ: SLDB ) just reported results for the first quarter of 2024. Solid Biosciences reported earnings per share of -64 cents.
05/15 07:52 EST - globenewswire.com
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —
04/10 19:32 EST - seekingalpha.com
Buy Solid Biosciences: Unpacking Its Main Value Driver
Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.
Buy Solid Biosciences: Unpacking Its Main Value Driver
Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.
04/05 04:54 EST - finbold.com
How this insider trader nailed every single stock trade
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
How this insider trader nailed every single stock trade
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
04/02 11:36 EST - zacks.com
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
04/01 07:45 EST - globenewswire.com
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003, the company's next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003, the company's next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.
03/28 11:31 EST - investors.com
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
03/13 07:44 EST - globenewswire.com
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 —
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 —
02/18 11:20 EST - 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
02/12 08:53 EST - 247wallst.com
Another Huge Buffett Purchase Highlights Recent Insider Buying
The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.
Another Huge Buffett Purchase Highlights Recent Insider Buying
The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.